The role of Meflin in promoting the antitumor effect of anti–mPD-1 antibody was also confirmed in another experimental setup, in which we orthotopically transplanted syngeneic EO771 breast cancer (BC) cells (House et al, 2020; Zheng et al, 2018) into the fourth right mammary fat pad of WT mice and Meflin-KO mice, followed by intraperitoneal administration of anti–mPD-1 antibody or control IgG on day 6, 9, and 12 after the transplantation (Fig 6D). This evidence concerns the gene ISLR and breast carcinoma.